Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

PHLAX PGIM Jennison Health Sciences A

  • Fund
  • PHLAX
  • Price as of: Sep 17, 2018
  • $52.52
  • - $0.70
  • - 1.32%
  • Category
  • Health & Biotech Equities

PHLAX - Profile

Vitals

  • YTD Return 17.2%
  • 3 Yr Annualized Return 7.7%
  • 5 Yr Annualized Return 17.1%
  • Net Assets $2.6 B
  • Holdings in Top 10 37.2%

52 WEEK LOW AND HIGH

$52.52
$43.29
$54.00

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.15%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 27.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of 2012-06-29

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 17.2%
  • 3 Yr Annualized Total Return 5.6%
  • 5 Yr Annualized Total Return 15.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.61%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name PGIM Jennison Health Sciences Fund
  • Fund Family Name PGIM Funds (Prudential)
  • Inception Date Jun 30, 1999
  • Shares Outstanding N/A
  • Share Class A
  • Currency USD
  • Domiciled Country United States
  • Manager David Chan

Fund Description

The Prudential Jennison Health Sciences Fund Class A (PHLAX) is an actively managed fund that focuses on the health care sector of the world’s equity markets. PHLAX can own drug, health care, medicine, medical devices, and biotechnology stocks and can invest in any market-cap size. The fund uses various fundamental analyses to uncover the best growth stocks within the health care sector.

Even with its low costs, PHLAX’s focus on riskier segments of the equity markets makes the fund a satellite position only within a broader equity portfolio. The fund is managed by Jennison Associates LLC.

PHLAX - Performance

Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 17.2% -89.3% 27.4% 12.50% 1
1 Yr 22.9% -14.8% 48.6% 24.32% 2
3 Yr 7.7% * -7.5% 22.4% 50.93% 3
5 Yr 17.1% * 8.6% 23.1% 21.50% 2
10 Yr 17.2% * 6.1% 18.7% 7.77% 1

* Annualized


Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 24.9% -19.5% 43.9% 15.45% 1
2016 -17.7% -29.8% 14.5% 67.27% 4
2015 -8.5% -20.4% 33.7% 81.82% 5
2014 18.0% -5.8% 48.1% 40.91% 3
2013 43.8% -3.1% 65.2% 37.61% 2

Total Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 17.2% -89.3% 27.4% 12.61% 1
1 Yr 16.1% -18.3% 48.6% 41.82% 3
3 Yr 5.6% * -14.2% 22.4% 62.96% 4
5 Yr 15.8% * 7.8% 23.1% 39.25% 2
10 Yr 16.5% * 6.1% 18.7% 11.65% 1

* Annualized


Total Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 24.9% -19.5% 43.9% 15.60% 1
2016 -17.7% -25.1% 39.1% 69.72% 4
2015 5.6% -16.6% 100.0% 70.64% 4
2014 52.2% -5.8% 79.8% 4.59% 1
2013 133.8% 0.0% 398.7% 6.48% 1

NAV & Total Return History

PHLAX - Holdings

Filings data as of: Jul 31, 2018

Concentration Analysis

PHLAX Category Low Category High PHLAX % Rank Quintile
Net Assets 2.6 B 17.5 M 50 B 13.39% 2
Number of Holdings 90 28 378 17.86% 3
Net Assets in Top 10 914 M 10.3 M 18.6 B 13.39% 2
Weighting of Top 10 37.2% 22.0% 73.7% 23.21% 4

Top 10 Holdings

  1. Biomarin Pharmaceutical Inc 5.80%
  2. UnitedHealth Group Inc 6.80%
  3. Humana Inc 2.99%
  4. bluebird bio Inc 2.32%
  5. Illumina Inc 4.42%
  6. Assembly Biosciences Inc 2.84%
  7. Sage Therapeutics Inc 3.23%
  8. Sarepta Therapeutics Inc 3.89%
  9. Centene Corp 2.53%
  10. Cigna Corp 2.38%

Asset Allocation

Weighting Category Low Category High PHLAX % Rank Quintile
Stocks
96.92% 91.14% 101.34% 24.11% 4
Cash
2.17% -0.07% 7.79% 10.71% 2
Other
0.77% -2.40% 4.78% 5.36% 2
Preferred Stocks
0.14% 0.00% 2.19% 8.93% 1
Convertible Bonds
0.00% 0.00% 0.26% 3.57% 3
Bonds
0.00% 0.00% 4.69% 3.57% 2

Stock Sector Breakdown

Weighting Category Low Category High PHLAX % Rank Quintile
Healthcare
95.26% 11.13% 99.44% 19.64% 3
Technology
1.65% 0.00% 66.03% 12.50% 3
Utilities
0.00% 0.00% 0.26% 1.79% 2
Real Estate
0.00% 0.00% 1.12% 2.68% 3
Industrials
0.00% 0.00% 8.36% 10.71% 3
Financial Services
0.00% 0.00% 5.94% 7.14% 3
Energy
0.00% 0.00% 0.08% 1.79% 2
Communication Services
0.00% 0.00% 0.00% 0.89% 2
Consumer Defense
0.00% 0.00% 1.31% 9.82% 3
Consumer Cyclical
0.00% 0.00% 8.32% 10.71% 3
Basic Materials
0.00% 0.00% 0.52% 2.68% 3

Stock Geographic Breakdown

Weighting Category Low Category High PHLAX % Rank Quintile
US
92.03% 64.75% 99.57% 12.50% 2
Non US
4.89% 0.00% 34.48% 27.68% 4

PHLAX - Expenses

Operational Fees

PHLAX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 1.15% 0.10% 4.31% 43.75% 2
Management Fee 0.72% 0.09% 1.25% 10.71% 3
12b-1 Fee 0.30% 0.00% 1.00% 7.59% 3
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

PHLAX Fees (% of AUM) Category Low Category High PHLAX Rank Quintile
Front Load 5.50% 2.50% 5.75% 7.69% 2
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

PHLAX Fees (% of AUM) Category Low Category High PHLAX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHLAX Fees (% of AUM) Category Low Category High PHLAX Rank Quintile
Turnover 27.00% 0.00% 699.00% 23.21% 2

PHLAX - Distributions

Dividend Yield Analysis

PHLAX Category Low Category High PHLAX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

PHLAX Category Low Category High Category Mode
Dividend Distribution Frequency Semi-Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

PHLAX Category Low Category High PHLAX % Rank Quintile
Net Income Ratio -0.61% -2.15% 1.46% 46.43% 3

Capital Gain Distribution Analysis

PHLAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

PHLAX - Managers

David Chan

Manager

Start Date

Jun 30, 1999

Tenure

19.18

Tenure Rank

1.9%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.


Debra Netschert

Manager

Start Date

Jan 28, 2015

Tenure

3.59

Tenure Rank

17.5%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.


Tenure Analysis

Category Low

0.0

Category High

21.0

Category Average

9.32

Category Mode

3.7